Search Results

You are looking at 91 - 100 of 420 items for :

  • "single agent" x
Clear All
Full access

Apar Kishor Ganti, Mollie deShazo, Alva B. Weir III and Arti Hurria

: Subset Analyses of Non–Age-Specific Trials Elderly-Specific Trials Single-Agent: The Elderly Lung Cancer Vinorelbine Italian Study Group (ELVIS) study, which was among the first randomized studies designed specifically for older patients

Full access

Saranya Chumsri, Ethan S. Sokol, Aixa E. Soyano-Muller, Ricardo D. Parrondo, Gina A. Reynolds, Aziza Nassar and E. Aubrey Thompson

using ICIs, particularly in immunogenic or “hot” tumors such as melanoma or lung cancer. In contrast, results of single-agent ICIs in less-immunogenic tumors, including breast cancer, have been less promising, particularly in immunologically “cold

Full access

Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar and Pierluigi Porcu

5-year estimated OS rate was 32.4%. 41 Until recently, data to guide the treatment of relapsed and refractory PTCL with various single agents (such as alemtuzumab, bortezomib, gemcitabine, lenalidomide, and cyclosporine) came from small single

Full access

Matthew Zibelman and Anthony J. Olszanski

ipilimumab improved OS from 9.1 to 11.2 months ( P <.001). 14 Notably, there was not an ipilimumab-alone arm on this trial, potentially calling into question a role for ipilimumab as a single agent in the first-line treatment of patients with metastatic

Full access

Tanner M. Johanns, George Ansstas and Sonika Dahiya

. 10 , 18 – 24 In total, adult HGG or GBM cases were composed of 4 GBM/eGBM, 9 aPXA, and 1 anaplastic ganglioglioma, with 10 patients treated with single-agent BRAFi (5 with vemurafenib, 5 with dabrafenib) and 4 treated with combination BRAFi/MEKi (all

Full access

Matthew Zibelman and Elizabeth R. Plimack

documented OS benefit, potential of a durable response, and favorable toxicity profile. Still, most patients do not benefit from receiving single-agent nivolumab. Thus, ongoing research is geared toward increasing clinical benefit, with 3 viable options to

Full access

Jing Xi, Aabha Oza, Shana Thomas, Foluso Ademuyiwa, Katherine Weilbaecher, Rama Suresh, Ron Bose, Mathew Cherian, Leonel Hernandez-Aya, Ashley Frith, Lindsay Peterson, Jingqin Luo, Jairam Krishnamurthy and Cynthia X. Ma

+ everolimus (n=12), exemestane + entinostat (n=2), or fulvestrant + palbociclib (n=2). The most common regimens after progression on palbociclib were single-agent capecitabine (n=21), eribulin (n=16), nab-paclitaxel (n=15), and exemestane + everolimus (n=12

Full access

Tomas G. Lyons and Mark E. Robson

study of single-agent veliparib showed a PFS of 5.2 months, with a response rate of 14% and 36% for patients with BRCA1 and BRCA2 mutations, respectively. 25 Results of combining veliparib with carboplatin and paclitaxel in the randomized phase II

Full access

Kenneth C. Anderson

, was developed. Ixazomib is taken only once weekly and has a favorable side-effect profile. Carfilzomib and ixazomib are now incorporated into the NCCN Guidelines, both as single agents and in combination with lenalidomide and dexamethasone, based on

Full access

Shumei Kato, Vivek Subbiah and Razelle Kurzrock

modulator. 1 Hence, it is reasonable to conclude that these 2 types of single agents given to patients with advanced refractory cancer are not effective. It is not justified to extrapolate from this limited data and conclude that all of precision medicine